AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Investment firm Carlyle announced on Monday it has rejigged its senior leadership ranks and named three of its veterans for ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $95.9, along with a high estimate of $150.00 and a low estimate of $64.00. Experiencing a 1 ...

Jefferies, TD Cowen and Leerink Partners are acting as joint book-running managers for the Convertible Notes Offering and the Common Stock Offering. LifeSci Capital is acting as lead manager for the ...